IMO-2055 + erlotinib + bevacizumab

IMO-2055 + erlotinib + bevacizumab is an investigational three-drug combination studied primarily in advanced or metastatic non-small cell lung cancer (NSCLC) patients who have progressed following chemotherapy. IMO-2055 is a synthetic, immunostimulatory oligonucleotide that acts as a Toll-like receptor 9 (TLR9) agonist, activating innate immunity and potentially enhancing tumor-directed immune responses[1][3][5][7]. Erlotinib is a small molecule, reversible tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptor (EGFR), used in various cancers including NSCLC. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and thus tumor growth[2][4][6][8]. The reported mechanism for this combination is to synergistically enhance antitumor efficacy by combining immune stimulation (IMO-2055), blockade of EGFR signaling (erlotinib), and suppression of tumor neoangiogenesis (bevacizumab). The triple therapy showed tolerable safety and anecdotal antitumor activity in early-phase clinical trials for heavily pretreated NSCLC patients[1][3][5][7].